NEW YORK (GenomeWeb) – OncoDNA said today that CyberKnife Sigulda will market and distribute its tumor profiling solutions for clinical use in Latvia.
Financial and other terms of the deal were not disclosed.
Gosselies, Belgium-based OncoDNA’s solutions guide oncologists in their treatment decision-making based on a solid or liquid molecular characterization of a tumor. They include tumor interrogation technologies — such as NGS, immunohistochemistry, and pyrosequencing — combined with an extensive clinical literature assessment, the firm said.
CyberKnife Sigulda was founded to assist in the fight against cancer, benign tumors, and other diseases that are treatable with radio surgery or radiation therapy.